CRESP 200MCG INJ. (PFS) – Composition, Uses and Medicine Enquiries
Product Overview
CRESP 200MCG INJ. (PFS) is listed as a prescription product containing Darbepoetin alfa 200MCG, marketed in the source catalogue by Dr Reddy’s Laboratories Ltd.
It belongs to the erythropoiesis-stimulating agent class and may be prescribed for selected anemia associated with chronic kidney disease or chemotherapy.
Its active ingredient stimulates bone marrow production of red blood cells.
Treatment suitability depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.
Hypertension and thrombotic risks require specialist monitoring.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Darbepoetin alfa | 200MCG |
Product Name: CRESP 200MCG INJ. (PFS)
Generic Name: Darbepoetin alfa
Brand Name: CRESP 200MCG INJ. (PFS)
Strength: 200MCG
Listed Marketer: Dr Reddy’s Laboratories Ltd
The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.
Therapeutic Category and Indication
CRESP 200MCG INJ. (PFS) belongs to the erythropoiesis-stimulating agent category.
It may be prescribed for selected anemia associated with chronic kidney disease or chemotherapy.
Darbepoetin alfa stimulates bone marrow production of red blood cells.
Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.
Hypertension and thrombotic risks require specialist monitoring.
Administration Information
The supplied product information identifies injection by a healthcare professional according to monitored haemoglobin targets.
Administration should follow the treating clinician’s instructions and the approved product label.
Patients should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.
The exact prefilled syringe presentation and administration schedule must be verified against the approved product information.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: CRESP 200MCG INJ. (PFS)
- Generic Name: Darbepoetin alfa
- Strength: 200MCG
- Company Name: Dr Reddy’s Laboratories Ltd
- Therapeutic Category: Erythropoiesis-Stimulating Agent
- Medicine Class: Erythropoiesis-Stimulating Agent (ESA)
- Indication: Selected anemia associated with chronic kidney disease or chemotherapy
- Administration: Injection by healthcare professional according to monitored haemoglobin targets
The product name includes the PFS designation. The exact dosage form, prefilled syringe presentation, pack size, batch, storage and expiry require verification from original manufacturer packaging and an authorised provider.
Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.
Prescription and Patient Safety
CRESP 200MCG INJ. (PFS) is listed as a prescription product and requires specialist supervision.
Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by the treating specialist.
Hypertension and thrombotic risks require specialist monitoring.
Patients should follow the approved product label and their healthcare professional’s instructions. The dose and treatment schedule should not be changed without medical advice.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.
Medinglobal does not itself sell, dispense, manufacture or export medicines.
Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.
How to Submit a CRESP 200MCG INJ. (PFS) Enquiry
To help identify the requested product, include the following details:
- Product name: CRESP 200MCG INJ. (PFS).
- Generic name: Darbepoetin alfa.
- Required strength: 200MCG.
- Required formulation and quantity.
- Destination country.
- Valid prescription or institutional documents, where required.
Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.
Frequently Asked Questions
What is CRESP 200MCG INJ. (PFS) used for?
It is associated with selected anemia related to chronic kidney disease or chemotherapy. The treating prescriber confirms the approved use.
What is the composition of CRESP 200MCG INJ. (PFS)?
The supplied catalogue lists Darbepoetin alfa 200MCG as its active ingredient. The composition should be verified against the original product packaging.
How is CRESP 200MCG INJ. (PFS) administered?
The supplied information identifies injection by a healthcare professional according to monitored haemoglobin targets.
Which company is listed for CRESP 200MCG INJ. (PFS)?
Dr Reddy’s Laboratories Ltd is listed as the marketer in the supplied product information.
Does CRESP 200MCG INJ. (PFS) require medical supervision?
Yes. Hypertension and thrombotic risks require specialist monitoring.
Can Medinglobal supply CRESP 200MCG INJ. (PFS) directly?
No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.




Reviews
There are no reviews yet.